← Insider Monitor
MYRIAD GENETICS INC logo
MYGN

MYRIAD GENETICS INC

Nasdaq · In Vitro & In Vivo Diagnostic Substances

1
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

Myriad Genetics develops and markets molecular diagnostic tests that assess genetic risk for diseases such as hereditary cancers, and offers testing related to prenatal screening, pharmacogenomics, and tumor profiling to guide treatment decisions.

Industry
In Vitro & In Vivo Diagnostic Substances
Headquarters
Salt Lake City, UT
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Davis Mark StevenDirectorSell$34KNov 18, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for MYGN.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable MYGN activity by email

Free alerts for the insider and congressional trades worth watching.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.